Clinical Trials in San Antonio

Showing 3161-3180 of 12,572 trials

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

NCT06240728

NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response. The goal of this first-in-human study is to learn whether NPX887 is safe and tolerable and shows a preliminary efficacy in participants with B7-H7 (HHLA2) expressing tumors at selected dose(s). The main questions it aims to answer are: * what is an appropriate dose to be given to participants? * are the side effects of treatment manageable? * what is the preliminary anti-tumor activities? Participants who are treated will receive an intravenous (IV) infusion of NPX887 if their disease has not progressed, and be closely monitored by the treating physicians.

Metastatic Malignant Neoplasm

NextPoint Therapeutics, Inc.144 participantsStarted Jan 2024

Baltimore, Maryland, United States • Boston, Massachusetts, United States • The Bronx, New York, United States +5 more locations

Active Not RecruitingPhase 1< 1 mile

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

NCT04648202

This is a Phase 1/1b, multicenter, open label study to evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies

Advanced CancerMetastatic Cancer

invoX Pharma Limited82 participantsStarted Nov 2020

New Haven, Connecticut, United States • Houston, Texas, United States • San Antonio, Texas, United States +6 more locations

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

Find Trials by Condition in San Antonio

A Study of LY3541105 in Healthy and Overweight Participants

A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

Clinical Investigation of the Next-Generation Intraocular Lenses

Post-Approval Study of the TREO Abdominal Stent-Graft System

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Adolescent Master Protocol

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel

Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain

Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome

Open Label Extension for 43USSA1812

BIG Study (Brain, Immune, and Gut Health Evaluation of Infants/Young Children Fed Infant Formula, and Later Supplemental Toddler Nutrition, With 5 Specific HMOs)

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)

Cough Reduction in IPF With Nalbuphine ER